November 15, 2012 ·
Leave a comment
The Medical Science Liaison Society, a non-profit focused on advancing the Medical Science Liaison career in the pharmaceutical, biotechnology, and medical device industries, has named Thought Leader Select’s Allison Murphy to its global advisory committee.
The MSL Society, led by Dr. Samuel Dyer from its Florida headquarters, is bringing the global MSL community together through a variety of educational and networking platforms, including webinars, white papers, conferences, and multiple social media outlets. Dr. Dyer and the MSL Society team of advisors are collaborating with several premier industry partners, including First Word Reports and EyeforPharma.
Prior to joining Thought Leader Select as a global sales consultant in 2012, Murphy spent the previous decade of her career working as a Medical Science Liaison at Eli Lilly and Company in the therapeutic area of Endocrinology. Murphy collaborated with multiple Key Opinion Leaders to drive Lilly’s medical initiatives in support of products aimed at treating conditions ranging from diabetes to growth disorders.
“I am very proud to be a part of the MSL Society’s global advisory committee,” stated Murphy. “I know first-hand from my days at Lilly that there weren’t enough of the right resources and networking opportunities for MSLs and Medical Affairs executives, to help them advance their careers and ... read more »
September 27, 2012 ·
Leave a comment
(CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a national engagement in gastroenterology with a top Canadian biopharmaceutical company.
The company, part of a select group of global leaders in drug development for products treating type and type II diabetes, approached Thought Leader Select for support with scientific advisory boards and continuing health education (CHE) initiatives across multiple Canadian provinces. Having already worked with Thought Leader Select to form a roster of key opinion leaders in Canadian endocrinology circles, the company will round out its roster of key opinion leaders by deploying Thought Leader Select’s team to assess the skills and experiences of registered nurses and clinical pharmacists around the country.
Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of registered nurses and pharmacists in multiple areas where they collaborate with leading physicians to advance the science of medicine and patient care, including basic and clinical research, scientific journal publishing, treatment guidelines, and more.
Throughout the remainder of the engagement, Thought Leader Select’s consulting team will provide strategic guidance, tactical recommendations for strengthening key opinion leader relationships in the nursing and pharmacy communities, and a suite of tools to promote collaborative work with KOLs.
“Thought ... read more »
February 28, 2012 ·
Leave a comment
Industry Insights from Paul Meade, M. Sc., MPH
There has been quite a lot of noise lately regarding the use of social network techniques to find key opinion leaders in the medical profession. Whether it’s through what some call social network analysis or the creation of health care professional-only social networks, proponents of these methods like to think that they are reinventing thought leadership and its metrics.
In fact, some advocates even suggest they can find more key opinion leaders in the medical field than by using other tried and tested, and sometimes validated approaches. Can this be true? Well, it depends on how these companies, and better yet, how the end users of their services, define thought leaders or key opinion leaders (KOLs).
There are those with backgrounds in information technology, as well as social sciences such as sociology and psychology, and other areas outside healthcare who are trying to redefine thought leadership in medicine to fit the template of the products they are selling. For example, some of them have taken concepts of social interactions and applied them to finding those medical experts that either publish together or even present at similar conferences. But just because someone writes a paper with someone else doesn’t mean they are both KOLs. In fact, the contrary is often the case.
So let’s back up and ... read more »
February 8, 2012 ·
Leave a comment
Thought Leader Select is looking for a dynamic, talented individual to fill its newest U.S. Sales Executive position.
Founded in 2006, Thought Leader Select is a firm that serves the biopharmaceutical industry by providing strategic counsel on the best ways to work with medical experts (known as “thought leaders” and “key opinion leaders”) and assessing experts within a host of therapeutic areas such as diabetes, oncology, and neurology.
Interested applicants should go to the company’s human resources site for more information on this exciting opportunity.
January 12, 2012 ·
Leave a comment
By Brian Castle and Kristen Smithwick
When most people think about thought leaders in medicine, specialists in oncology, neurology, rheumatology and other therapeutic areas immediately come to mind. However, with the proliferation of illnesses and conditions ranging from diabetes and obesity to asthma, gastrointestinal diseases and psychiatric disorders, key opinion leaders in primary care and allied health professions are more important than ever.
In addition to the growing incidence of several “lifestyle” conditions, the structure of U.S. healthcare dictates that people suffering in these areas see their primary care physicians (PCPs), nurses, nurse practitioners, physician assistants, and pharmacists with much greater frequency than their specialists. As a result, more PCPs and allied health professionals are joining their specialist colleagues in all of the critical areas that define thought leadership, including publishing, basic and clinical research, clinical practice, speaking, and advocacy involvement.
Thought Leader Select has conducted multiple assessments of thought leader populations in a variety of therapeutic areas, with particular attention to the impact of PCPs, also known as general practitioners, in areas of treatment as diverse as diabetes, allergies, infectious disease, and gastrointestinal conditions. Primary care physicians, along with their nurse practitioner (NP), physician assistant (PA), and registered nurse colleagues, consistently distinguish themselves in many of the traditional areas of thought leadership once assumed to be the domain of specialists and sub-specialists.
Leaders ... read more »
January 6, 2011 ·
The International Diabetes Federation Atlas (http://www.diabetesatlas.org) reports that 285 million people aged 20-79 years globally have diabetes, a disease impacting most countries. According to the Centers for Disease Control (CDC) 2007 National Diabetes Fact Sheet, diabetes affects 23.6 million people or 7.8% of the U.S. population. It is no wonder, then, that millions of dollars are spent every year to fund research that will treat and perhaps cure the disease.
Certainly, endocrinologists and a host of other specialty physicians participate in basic and clinical research sponsored by government entities, academic institutions, professional societies and biopharmaceutical companies. However, primary care physicians (PCPs) are also widely involved in diabetes research. The diversity of patient populations and illnesses treated by PCPs make them desirable investigators, especially when the research seeks to understand diabetic co-morbidities, how the disease affects different populations, and better ways to help patients manage their diabetes.
Thought Leader Select recently studied the research activities of more than 150 primary care thought leaders (TLs) in the United States and identified several interesting trends about their research activities in general, as well as those related to diabetes research. We found that 86% of primary care TLs are regularly involved in basic and clinical research efforts. Of those 134 actively conducting research, more than half are involved in diabetes-related projects (see Chart 1). More ... read more »
August 2, 2010 ·
Key opinion leaders (KOLs) are health care leaders who make a high-impact footprint while advancing medical science. Thought Leader Select specializes in delivering objective, validated data on the skills and experiences of KOLs, so that pharmaceutical companies can seek their advice and guidance in the development of new medicines.
Over the past several years, Thought Leader Select has studied physician key opinion leaders who treat diabetes and analyzed their involvement in many areas, including clinical research, treatment guidelines involvement, publishing, reimbursement involvement and participation in advocacy efforts. In a recent assessment of nearly 500 diabetes KOLs across the United States, Thought Leader Select examined their participation in patient advocacy activities. Using keywords to link these KOLs with such activities, Thought Leader Select found that 62% of physicians regularly take part in patient advocacy efforts, such as participation in advocacy organizations, patient education or legislative efforts (see Chart 1).
Of the 301 KOLs with advocacy involvement, most take part in five or fewer activities, while only 3% of them boast 10 or more advocacy activities and/or awards. In addition to activities through the American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) – especially the American College of Endocrinology’s Power of Prevention (POP) program – top advocacy initiatives and organizations include:
• Taking ... read more »
June 23, 2010 ·
Leave a comment
A recent PharmaTimes article highlighted the efforts of the largest public/private partnership in the pharmaceutical industry, Europe’s Innovative Medicines Initiative (IMI). The IMI, jointly funded for 2 billion euros by the European Commission and the industry group, the European Federation of Pharmaceutical Industries and Associations (EFPIA), seeks to address the development and delivery issues for critical new medicines that may be too large for an individual institution or company to tackle alone.
According to PharmaTimes, the IMI focuses on “unmet needs common to the pharmaceutical industry and patients – the key concepts being pre-competitive research, open innovation and patient-tailored therapies.” Now in its third year accepting proposals, the initiative will target a number of new developments in pharmaceuticals and patient education, including the development of personalized medicine approaches for the treatment of diabetes and a variety of training programs for creating “informed patients.”
Ongoing projects like the Innovative Medicines Initiative and Italy’s Drug Development and Discovery Unit (see our previous post about the D3 here) are opening up greater opportunities for the pharmaceutical industry to pool its resources and work with the medical community for better public health.